ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 26, 2013--
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced the
closing of its underwritten registered public offering of an aggregate
of 3,000,000 shares of its common stock, including 391,304 shares of
common stock sold pursuant to the full exercise by the underwriters of
their option to purchase additional shares. All of the shares were sold
at a price to the public of $30.00 per share. The aggregate net proceeds
to the company from this offering are approximately $84.5 million, after
deducting underwriting discounts and commissions and estimated offering
BofA Merrill Lynch acted as the sole book-running manager of the
offering. Leerink Swann acted as joint lead manager. William Blair, JMP
Securities, Dougherty & Company, Feltl & Company and Wunderlich
Securities acted as co-managers.
The shares of common stock were sold pursuant to the company's effective
shelf registration statement.
The offering of these securities was made only by means of a prospectus
and related prospectus supplement, copies of which may be obtained by
visiting EDGAR on the Securities and Exchange Commission’s website at http://www.sec.gov.
Alternatively, copies of the final prospectus supplement and base
prospectus related to the offering may be obtained by contacting BofA
Merrill Lynch at 222 Broadway, New York, NY 10038, Attention: Prospectus
Department or by e-mailing firstname.lastname@example.org.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of CSI, and there will
not be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical
device company focused on developing and commercializing innovative
solutions for treating vascular and coronary disease. The company’s
Orbital Atherectomy Systems treat calcified and fibrotic plaque in
arterial vessels throughout the leg and heart in a few minutes of
treatment time, and address many of the limitations associated with
existing surgical, catheter and pharmacological treatment alternatives.
The U.S. FDA granted 510(k) clearance for the use of the Diamondback
Orbital Atherectomy System in August 2007. To date, over 125,000 of
CSI’s devices have been sold to leading institutions across the United
States. In October 2013, the company received FDA approval for the use
of the Diamondback Orbital Atherectomy System in coronary arteries.
Source: Cardiovascular Systems, Inc.
For Cardiovascular Systems, Inc.